Annovis Bio Inc. - notizie pubblicate 175 - letture 3.747
ANNOVIS BIO INC.
April 20, 2023ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST
Thu, 20 apr 2023 company to hold r&d webcast today at 4:00 pm et to review ongoing clinical programs in alzheimer's disease and parkinson's disease updated webcast link and dia ...
ANNOVIS BIO INC.
April 19, 2023ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST
Wed, 19 apr 2023 phase 2/3 ad study continues to make steady progress in patient recruitment company to hold r&d webcast on thursday, april 20thto review ongoing clinical progr ...
ANNOVIS BIO INC.
Preliminary Proxy Statement - Form PRE 14A
United states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. ...
ANNOVIS BIO INC.
April 13, 2023ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS
Thu, 13 apr 2023 webcast to be held on thursday, april 20th at 4pm edt. berwyn, pa., april 13, 2023/prnewswire/ -- annovis bio, inc. (nyse: anvs) ("annovis" or the " ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ANNOVIS BIO INC.
April 11, 2023ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION
Tue, 11 apr 2023 berwyn, pa., april 11, 2023/prnewswire/ -- annovis bio, inc. (nyse: anvs) ("annovis" or the "company"), a clinical-stage drug platform company ...
ANNOVIS BIO INC.
Termination of Material Agreement - Form 8-K
United states securities and exchange commission washington, dc 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report ...
ANNOVIS BIO INC.
Material Agreement - Form 8-K
United states securities and exchange commission washington, dc 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report ...
ANNOVIS BIO INC.
April 3, 2023Annovis Bio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer annovis bio inc. pub ...
ANNOVIS BIO INC.
ANNOVIS BIO ANNOUNCES FOURTH QUARTER and full year 2022 financial RESULTS AND PROVIDES CORPORATE UPDATE - Form 8-K
Annovis bio announces fourth quarter and full year 2022 financial results and provides corporate update berwyn, penn., april 3, 2023 /prnewswire/ -- annovis bio, inc. (nyse: anvs) ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti